KYMRIAH
NDC 0078-0846 · Novartis Pharmaceuticals Corporation
Generic nametisagenlecleucel
Dosage formINJECTION, SUSPENSION
RouteINTRAVENOUS
Active ingredient(s)TISAGENLECLEUCEL
Strength2000000 1/1
Pharmacologic classCD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT]
Marketing categoryBLA
Packages
0078-0846-19 — 1 INJECTION, SUSPENSION in 1 BAG (0078-0846-19)
Billed under HCPCS
Q2042 — Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Medicare Part B payment limit (ASP + 6%): $611693.17
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
0078-0958 — tisagenlecleucel